UC San Diego UC San Diego Previously Published Works

Title

The relationship between dopamine receptor D1 and cognitive performance

Permalink

https://escholarship.org/uc/item/3vj850r7

Journal Schizophrenia, 1(1)

ISSN

2754-6993

Authors

Tsang, Jonathan Fullard, John F Giakoumaki, Stella G <u>et al.</u>

Publication Date 2015

DOI

10.1038/npjschz.2014.2

Peer reviewed

ARTICLE OPEN The relationship between dopamine receptor D1 and cognitive performance

Jonathan Tsang¹, John F Fullard^{2,3}, Stella G Giakoumaki⁴, Pavel Katsel², Pavel Katsel², Vasiliki Eirini Karagiorga⁵, Tiffany A Greenwood⁶, David L Braff^{6,7}, Larry J Siever^{2,8}, Panos Bitsios^{9,10}, Vahram Haroutunian^{2,3,8} and Panos Roussos^{2,3,8,11,12}

BACKGROUND: Cognitive impairment cuts across traditional diagnostic boundaries and is one of the most typical symptoms in various psychiatric and neurobiological disorders.

AIMS: The objective of this study was to examine the genetic association between 94 candidate genes, including receptors and enzymes that participate in neurotransmission, with measures of cognition.

METHODS: The Clinical Dementia Rating (CDR), a global measure of cognition, and genotypes derived from a custom array of 1,536 single-nucleotide polymorphisms (SNPs) in 94 genes were available for a large postmortem cohort of Caucasian cases with Alzheimer's disease (AD), schizophrenia and controls (n = 727). A cohort of healthy young males (n = 1,493) originating from the LOGOS project (Learning On Genetics Of Schizophrenia Spectrum) profiled across multiple cognitive domains was available for targeted SNP genotyping. Gene expression was quantified in the superior temporal gyrus of control samples (n = 109). The regulatory effect on transcriptional activity was assessed using the luciferase reporter system.

RESULTS: The rs5326-A allele at the promoter region of dopamine receptor D1 (*DRD1*) locus was associated with: (i) poorer cognition (higher CDR) in the postmortem cohort ($P = 9.325 \times 10^{-4}$); (ii) worse cognitive performance relevant to strategic planning in the LOGOS cohort (P = 0.008); (iii) lower *DRD1* gene expression in the superior temporal gyrus of controls (P = 0.038); and (iv) decreased transcriptional activity in human neuroblastoma (SH-SY5Y) cells (P = 0.026).

CONCLUSIONS: An interdisciplinary approach combining genetics with cognitive and molecular neuroscience provided a possible mechanistic link among *DRD1* and alterations in cognitive performance.

npj Schizophrenia (2015) 1, Article number: 14002; doi:10.1038/npjschz.2014.2; published online 4 March 2015

INTRODUCTION

Cognitive impairment is one of the most prevalent symptoms associated with various psychiatric and neurobiological disorders, including schizophrenia and Alzheimer's disease (AD).¹ Independent of the diverse etiopathogenetic mechanisms associated with different diseases, multiple studies have demonstrated the important modulatory role of neurotransmission on cognitive function.² Therefore, the pathological alterations of neurotransmitter systems might contribute to cognitive impairment and/or may account for the progression of cognitive decline.

The Clinical Dementia Rating (CDR) is an interviewer-based quantitative variable that assesses a person's cognitive and functional performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.³ On the basis of CDR classification, subjects are grouped as no cognitive deficits (CDR = 0), questionable dementia (CDR = 0.5, sometimes classified and mild cognitive impairment), mild dementia (CDR = 1.0), moderate dementia (CDR = 2.0), and severe-to-terminal dementia (CDR = 3.0–5.0). CDR is a global measure of cognition, which is abnormal across many disorders, including schizophrenia⁴ and AD.⁵

The purpose of this study was to examine the genetic association between 94 candidate genes, including receptors and enzymes that participate in neurotransmission, and CDR in a large postmortem cohort of cases with AD, schizophrenia, and controls. Targeted genotyping was done using the Consortium on the Genetics of Schizophrenia (COGS) single-nucleotide polymorphism (SNP) array. This is a custom array that was used previously to examine the genetic association of candidate genes with multiple schizophrenia endophenotypes.⁶ It includes 1,536 SNPs in 94 genes, selected on the basis of previous evidence for genetic association with schizophrenia or cognition and molecular pathways discovered through gene expression, brain imaging, or model organism studies. The majority of candidate genes are involved in synaptic transmission signaling, including glutamate, GABA, dopamine, and serotonin. In an attempt to provide a proofof-principal confirmation of the most significant association in the postmortem study (a SNP is the promoter region of the dopamine D1 receptor), the association of this SNP with cognitive function was evaluated in an independent living young adult cohort (LOGOS sample). To gain additional functional support for our findings, we then tested the regulatory potential of the most

¹Icahn School of Medicine at Mount Sinai, New York, NY, USA; ²Department of Psychiatry, New York, NY, USA; ³Friedman Brain Institute, New York, NY, USA; ⁴Department of Psychology, University of Crete, Rethymno, Crete, Greece; ⁵Department of Psychiatry, Icahn School of Medicine at Mount Sinai, Athens, Greece; ⁶Department of Psychiatry, University of California, San Diego, CA, USA; ⁷VISN-22 Mental Illness Research, Education, and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA; ⁸James J. Peters VA Medical Center, Mental Illness Research Education and Clinical Center (MIRECC), 130 West Kingsbridge Road, Bronx, NY, USA; ⁹Department of Psychiatry, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece; ¹⁰Computational Medicine Laboratory, Institute of Computer Science at FORTH, Heraklion, Greece; ¹¹Department of Genetics and Genomic Sciences, New York, NY, USA and ¹²Institute for Genomics and Multiscale Biology, New York, NY, USA.

Received 18 September 2014; revised 14 October 2014; accepted 15 October 2014



2

np

significant locus in human brain gene expression and *in vitro* luciferase experiments.

MATERIALS AND METHODS

Subjects

Brain tissue samples. Brain tissue specimens were obtained from the Icahn School of Medicine at Mount Sinai and the JJ Peters VA Medical Center MIRECC Brain Bank. The precise tissue handling procedures have been described in detail previously.⁷⁻¹⁰ All antemortem neuropsychological, diagnostic, and autopsy protocols were approved by the Icahn School of Medicine at Mount Sinai and other relevant Institutional Review Boards. Each sample has been extensively characterized on the basis of clinical and neuropathological criteria in diagnostically relevant (Consortium to Establish a Registry for Alzheimer's Disease) brain regions,¹¹ including the: (i) CDR^{3,12} (ii) density of neuritic plaques; and (iii) distribution of neurofibrillary tangle pathology using Braak neuropathology staging.¹³ For more details, see Supplementary Methods. The CDR was used as the primary measure of dementia severity. A multi-step consensus-dependent approach was applied to the assignment of CDR scores based on cognitive and functional status during the last 6 months of life, as described previously.^{9,10} Medical histories and records were reviewed for possible indirect causes of cognitive impairments such as renal disease, delirium, sepsis, etc. When available, longitudinal neuropsychological assessment results were also considered in deriving the final consensus CDR score.

Healthy individuals. A total of N = 1,493 healthy males (age mean \pm s.d.: 22.05 ± 3.45 , range: 18–30 years), who were recruited for the LOGOS (Learning on Genetics of Schizophrenia) study, underwent cognitive assessment and consented to providing DNA. Detailed description of the LOGOS study and the inclusion and exclusion criteria has been published previously.¹⁴⁻¹⁹ Briefly, a review of the participants' medical history was taken, and the Mini-International Neuropsychiatric Interview,²⁰ urine toxicology, and IQ testing with the Raven's Progressive Matrices²¹ were performed. The study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Ethics Committee of the University of Crete, the Executive Army Bureau, and the Bureau for the Protection of Personal Data of the Greek State. All subjects were administered the Wisconsin Card Sorting Test²² assessing set-shifting and rule learning abilities, the Word Lists task²³ assessing verbal learning and memory, the Iowa Gambling task²⁴ assessing emotional decision making and the N-back Sequential Letter task²⁵ assessing working memory. They were also administered selected tasks from the Cambridge Neuropsychological Test Automated Battery: spatial working memory and strategy formation were assessed with the Spatial Working Memory task,²⁶ sustained attention and vigilance were assessed with the Rapid Visual Information Processing task, $^{\rm 27}$ and planning and problem solving were assessed with the Stockings of Cambridge.²⁶ For more details see Supplementary Methods.

DNA extraction and genotyping

Brain tissue samples. Samples of DNA from the postmortem cohort were extracted from the superior temporal gyrus using the Genomic DNA-Tissue MiniPrep kit (Zymo Research, Irvine, CA, USA). Genotyping was performed blind to phenotype measures using the COGS SNP array.

Healthy individuals. DNA from the LOGOS cohort was extracted from blood or cheek swab samples, using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genotyping of *DRD1* rs5326 was performed blind to phenotype measures by LGC Genomics (Herts, UK) (http://www. lgcgenomics.com/) with a competitive, allele-specific PCR system. The call rate for rs5326 was 98.46% and genotype frequencies were distributed in accordance with Hardy–Weinberg equilibrium ($\chi^2 = 0.35$; P = 0.56). Genotyping quality control for each SNP was performed in 50 randomly selected samples by duplicate checking (rate of concordance in duplicates > 99%). All the subjects were of Caucasian ancestry on the basis of self-report, which was confirmed for a subset of the cohort (833 out of 840 subjects) on the basis of EIGENSOFT analysis^{28,29} of genome-wide genotyping SNP profiling with the Illumina HumanOmniExpress BeadChip¹⁹ (San Diego, CA, USA). On the basis of these data, the self-report identification of the Caucasian ancestry is 99.2% (833/840)

reliable, which makes genetic inhomogeneity of the tested population unlikely.

RNA extraction and real-time quantitative PCR

Total RNA was extracted from 50 mg of frozen tissue prepared from the superior temporal gyrus, as described in detail elsewhere.^{18,19,30} Brain specimens from 109 controls samples with Caucasian ancestry were used. The messenger RNA (mRNA) level of *DRD1* was measured by quantitative PCR using TaqMan probes and primer sets (Applied Biosystems, Foster City, CA, USA). TaqMan probe identification numbers are listed in Supplementary Table 1. For relative quantification of mRNA expression, geometric means of the expression of three housekeeping genes (*GUSB*, *PPIA*, and *RPLPO*) were calculated using the standard curve method.

Transient transfection and luciferase assays

Luciferase reporter plasmids were constructed by cloning the regulatory sequence containing rs5326 into the pGL4.11 vector (Promega, Madison, WI, USA) upstream of luc2P. The regulatory sequence of rs5326 G and A alleles ± 250 bp upstream/downstream (hg19; chr5:174,869,946-174,870,446) was introduced at the 5' and 3' using Kpnl and Xhol. We sequenced the inserted portions of the constructs to verify the nucleic acid sequences and the location of the SNP. Human neuroblastoma (SH-SY5Y) cells were transfected with each reporter vector (450 ng) and the Renilla luciferase expression vector pRL-TK (200 ng, Promega) using Lipofectamine 2000 (3 µl:1 µg Lipofectamine: DNA) (Invitrogen, Grand Island, NY, USA) in 200 µl Opti-MEM (Invitrogen) in 12-well plates. SH-SY5Y were grown in 1 ml of 1:1 mixture of DMEM and Ham's F12 medium supplemented with 10% fetal bovine serum. The media was not changed after the addition of the transfection reagents. Twenty-four hours after transfection, cells were collected and lysed by the addition of 250 µl of Passive Lysis Buffer (Promega). The luciferase activity in the cell lysates was determined using the Dual Luciferase Reporter System (Promega) in guadruplicates. The experiment was repeated five times as independent experiments. Firefly luciferase activities were normalized to that of Renilla luciferase and expression relative to the empty pGL4.11 vector was noted.

Statistical analysis

Demographics data were compared among groups using Kruskal–Wallis (continuous, nonparametric variables), analysis of variance (continuous, parametric variables) or chi-square (categorical variables). All statistics were two-tailed, and significance was set at P < 0.05.

Brain tissue samples. The preprocessing of SNP data and genetic analysis was performed with Plink (Version 1.07).³¹ More specifically, individuals were removed if they were outliers with respect to estimated heterozygosity (more than 3 s.d.) or had missing SNPs > 5%. SNPs were removed if: missing genotype rate > 5%; Hardy–Weinberg equilibrium $P < 10^{-3}$, minor allele frequency < 5%. For any pair of subjects with cryptic relatedness (pi-hat > 0.125 in PLINK, the sample with the lower call rate was eliminated. After QC, we had genotype profiling for 1,093 SNPs in 727 individuals (148 controls, 349 cases with AD, and 230 cases with schizophrenia) with total genotyping rate 99.9%. All the subjects were of Caucasian ancestry on the basis of self-report, which was confirmed for a subset of the cohort (310 out of 318 subjects or 97.5%) on the basis of EIGENSOFT analysis^{28,29} of genome-wide genotyping SNP profiling using the Affymetrix SNP 6.0 array (Santa Clara, CA, USA). We used a linear regression model to examine the association of CDR and genotypes across diagnostic groups:

$$\begin{split} \mathsf{CDR} &= \beta_0 + \beta_\mathsf{G}\mathsf{G} + \beta_\mathsf{Sex}\mathsf{Sex} + \beta_\mathsf{Age}\mathsf{Age} + \beta_\mathsf{Scz}\mathsf{Scz} + \beta_\mathsf{AD}\mathsf{AD} + \beta_\mathsf{G\times Scz}\mathsf{GScz} \\ &+ \beta_\mathsf{G\times AD}\mathsf{GAD}, \end{split}$$

where $\beta_{\rm G}$ is the parameter of interest quantifying the association between a genotype G and the mean of CDR controlling for sex, age, disease status —schizophrenia (Scz) and AD, and disease by genotype interaction for schizophrenia (G×Scz) and AD (G×AD). To correct for multiple testing and reduce the probability of type I error, empirical *P* values ($P_{\rm emp}$) were estimated on the basis of 100,000 permutations.

Healthy individuals. For the sake of data reduction and variables' classification we subjected the outcome variables from the cognitive tasks to principal component analysis (PCA). For PCA, the varimax rotation method was used and components with eigenvalues >1 and factor

loadings >0.5 were accepted. Analysis of covariance was used for comparison of cognitive performance among genotype groups with age and smoking status as covariates. *P* values were Bonferroni corrected by dividing 0.05 by the number of tested cognitive domains.

Gene expression and luciferase experiments. Pearson correlations were performed to examine the relation of potential confounds (age, gender, postmortem interval, RNA integrity number) with *DRD1* gene expression. We used a linear regression model to examine the association of *DRD1* gene expression and genotypes using RNA integrity number and age as covariates. Independent *t*-test was used for the analysis of the luciferase *in vitro* experiments.

RESULTS

Association of COGS SNPs with CDR in postmortem cohort

The association of COGS SNPs with CDR was examined across all groups (controls and cases with schizophrenia and AD) using a linear regression model. The strongest association was observed for rs5326 (β =0.74; P=9.325 × 10⁻⁴), which survived corrections for multiple testing (P_{emp} =0.004). Figure 1 and Supplementary Table 2 shows the association between CDR and COGS SNPs. Separate analysis of CDR in diagnostic groups, showed that rs5326 had the strongest association in controls (β =0.71; P=9.78 × 10⁻⁵) and cases with AD (β =0.86; P=2.81 × 10⁻⁴), while ranked third in cases with schizophrenia (β =0.61; P=8.05 × 10⁻⁴). The rs5326 is positioned in the promoter region of dopamine receptor D1 (*DRD1*).

Association of DRD1 rs5326 with cognitive performance in LOGOS There was a significant difference among genotype groups (P < 0.05) for age and smoking history (Supplementary Table 3) and both variables were added as covariates in the analysis of covariance. Eigenvalues for nine cognitive domains were derived on the basis of PCA of 22 outcome variables from seven cognitive tasks (Supplementary Table 4). The rs5326-A allele was associated with increased latency in a cognitive domain relevant to strategic planning (F(2,1465) = 5.847; η^2 = 0.008; P = 0.003) based on analysis of covariance comparison using age and smoking status as covariates (Figure 2a). Post hoc comparisons with the Bonferroni test correction revealed that the G/G group had lower latencies for strategic planning than the G/A (P = 0.033) or the A/A (P = 0.039) groups. Higher strategic planning latencies indicate increased mean initial and subsequent thinking time during the Stockings of Cambridge task.

Association of rs5326 with expression of *DRD1* mRNA in human brain and transcriptional activity

The rs5326-A allele was significantly associated with decreased *DRD1* gene expression ($R^2 = 0.124$; $\beta = -0.353$; P = 0.038; Figure 2b). RIN and age were included as covariates in the linear regression model, as there were nominally significant differences (P < 0.1) among genotype groups (Supplementary Table 5) and RIN was also positively correlated with *DRD1* gene expression (Pearson's r = 0.271; P = 0.004). The association of rs5326 with *DRD1* gene expression remain significant in permutation analysis of 100,000 random sets of genotypes relative to *DRD1* gene expression (empirical P = 0.008).

The effect of rs5326 on transcriptional activity was examined in *in vitro* experiments. Compared with the reference rs5326 G allele, the A variant was associated with decreased transcriptional activity in human neuroblastoma (SH-SY5Y) cells (20%; P = 0.026; Figure 2c).

DISCUSSION

This study applied an interdisciplinary approach combining genetics with cognitive and molecular neuroscience and provided a possible mechanistic link between DRD1 gene variants and expression and cognitive performance. We initially performed a targeted genetic analysis in a clinically and neuropathologically characterized postmortem cohort, using an informative panel of SNPs positioned within genes that affect and regulate synaptic transmission (COGS SNP array).⁶ From the 1,093 SNPs selected for association testing, rs5326 showed the strongest effect on CDR, a global measurement of cognition. For further exploration of the genetic association with cognition, we examined the association of rs5326 across nine different cognitive domains in the LOGOS cohort. We found a significant association of rs5326 with a PCA factor best described as strategic planning. Because the rs5326 is positioned at the promoter region of DRD1, we examined the regulatory effect of this variant on transcriptional activity. The risk rs5326 allele was associated with decreased DRD1 gene expression and luciferase transcriptional activity. These results replicate and extend previous findings on the association of the DRD1 with neurocognitive function.

The role of dopaminergic neurotransmission in modulating neurocognitive function is well established.³² The dopamine D1 receptor is abundantly expressed in the prefrontal cortex (PFC).³³ Infusion of D1 receptor antagonists into PFC in nonhuman primates induces deficits in working memory task.³⁴ In human subjects, administration of a mixed D1/D2 agonist facilitates




Figure 1. Genetic association analysis of 1,093 COGS SNPs and CDR in 727 individuals. Each SNP association is represented by a dot. The blue line represents the Bonferroni multiple testing correction threshold ($P < 4.58 \times 10^{-5}$). The strongest association was observed for rs5326.

D1, gene expression and cognition J Tsang et al b С а 2.5 12 0.7 0.6 10 0.5 DRD1 gene expression **Relative luminescence** 0.4 Planning (LOGOS) 1.5 0.3 0.2 0.1 0.5 0 Gle G/A A/A -0.1 0 G/G G/A A/A pGL4 G А -0.2

Figure 2. Association of *DRD1* rs5326 with (**a**) cognitive performance (Strategic planning) in the LOGOS cohort (F(2,1465) = 5.847; $\eta^2 = 0.008$; P = 0.003), (**b**) *DRD1* gene expression ($R^2 = 0.124$; $\beta = -0.353$; P = 0.038) and (**c**) relative luciferase activity in human neuroblastoma (SH-SY5Y) cells (P = 0.026). Error bars represent s.e.m. *P < 0.05; **P < 0.005.

working memory, while the selective D2 agonist has no effect, indicating the important modulatory role of dopamine D1 receptor on neurocognitive function.³⁵ This has led to the development of hypotheses that D1 agonists represent a promising approach to the treatment of cognitive impairment.³⁶

Multiple studies have provided evidence supporting an inverted U-shaped model between PFC dopaminergic signaling and performance in PFC-dependent cognitive tasks.^{37,38} The relationship of genetic variants within catechol-O-methyltransferase gene and cognitive function is well established.^{39–43} It has been demonstrated that tolcapone, a selective inhibitor of the catechol-O-methyltransferase enzyme, improves cognitive performance only in individuals that have lower capacity of PFC DA neurotransmission system, stratified according to their genetic background.^{39–41} We found that the rs5326 is a functional SNP with a potential important role in 'placing' human subjects on the low end of the inverted U-shaped curve, contributing to the impaired cognitive function and predicting the beneficial effect of D1 agonists on cognition.

The data presented here provide direct evidence for the association of low-levels of cortical *DRD1* mRNA gene expression, which is determined by genetic factors, with neurocognitive performance. The D1 receptor is affected by AD^{44,45} and schizo-phrenia,^{46,47} and decreases with age.^{48,49} Here, we applied a statistical model that does consider the confound effect of disease status and age. In addition, the strong effect of rs5326 on CDR was also observed in control brain samples, while a similar effect on cognitive function was observed in healthy young males. All the above indicate that the association of CDR with rs5326 is not limited only in cohorts with low cognitive reserve. One limitation is that the LOGOS cohort includes only healthy young males and caution must be exercised when considering our findings in the context of the general population.

A previous study did not find a significant association among rs5326 and *DRD1* gene expression.⁴⁷ The inconsistency of our results might be secondary to differences in the characteristics of the human postmortem cohort, including younger controls (mean age was 40, where variation in cognitive performance may be less) and mixed ethnic population. One limitation of our study is that we did not explore the effect of the rs5326 on protein abundance and D1 receptor availability. While ~40% of the variation in protein concentration can be explained by knowledge of mRNA abundances, additional mechanisms such as posttranscriptional, translational regulation, and degradation rates, acting through miRNAs may fine tune protein abundance at the surface of neurons on

the basis of gene expression data is challenging and possibly misleading. Another limitation is that the gene expression profiling was conducted in a single brain region (superior temporal gyrus). A previous study found that among 15 cortical regions, the superior temporal gyrus shows the highest transcriptional vulnerability associated with CDR.⁷ However, other regions, such as dorsolateral prefrontal cortex, mediate cognitive functions normally associated with DRD1 function (e.g., planning, working memory, etc.) and should be further examined in future gene expression studies.

Overall, the data presented in this study provide a mechanistic link between *DRD1* availability and cognitive performance across diagnostic groups. Additional support for the potential of targeting neurocognitive deficits through D1 receptor agonists is provided. Future studies should explore the effect of D1 receptor agonists on improving cognitive function in an inverted U-shaped dependent manner, taking into consideration the *DRD1* genetic background.

ACKNOWLEDGMENTS

The authors thank Gary Hardiman, for assisting with the genotyping in the postmortem cohort and the COGS consortium for developing the SNP array. The authors thank the participants and the personnel of the Military Training Camp of Candidate, Supply Army officers (SEAP) in Heraklion, Crete for their help with the study. We acknowledge funding support from Veterans Affairs Merit grant BX002395 (P.R.), the Brain Behavior Research Foundation (P.R.), the American Psychiatric Association-Merck & Co. Early Academic Career Research Award (P.R.), the National Institutes of Health (P01-AG02219, P50-AG05138, MH066392 to V.H.), Veteran Administration MIRECC, Leir Foundation, the Friedman Brain Institute at Icahn School of Medicine at Mount Sinai and the Icahn Institute for Genomics and Multiscale Biology at Icahn School of Medicine at Mount Sinai.

CONTRIBUTIONS

PR, PB, LJS, and VH designed and supervised the research. PR performed the statistical analysis. SGG and PB provided the LOGOS data. TAG and DLB designed the COGS SNP array. LJS and VH provided the postmortem data. PB and JFF performed the luciferase assay. JT, PK, and PR performed the gene expression studies. JT, VH, LJS, and PR prepared the manuscript. PR had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

COMPETING INTERESTS

The authors declare no conflict of interest.

FUNDING

This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. The funders had no role in study design, execution, analysis, or manuscript preparation.

REFERENCES

- 1 Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012; 11: 141–168.
- 2 Xu Y, Yan J, Zhou P, Li J, Gao H, Xia Y et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2012; 97: 1–13.
- 3 Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology* 1993; **43**: 2412–2414.
- 4 Rapp MA, Schnaider-Beeri M, Purohit DP, Reichenberg A, McGurk SR, Haroutunian V et al. Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients. *Schizophr Res* 2010; 116: 90–96.
- 5 Schnaider Beeri M, Silverman JM, Schmeidler J, Wysocki M, Grossman HZ, Purohit DP et al. Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology. *Dement Geriatr Cogn Disord* 2008; 25: 392–398.
- 6 Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ *et al.* Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. *Am J Psychiatry* 2011; **168**: 930–946.
- 7 Haroutunian V, Katsel P, Schmeidler J. Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. *Neurobiol Aging* 2009; **30**: 561–573.
- 8 Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281: 1401–1406.
- 9 Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 1998; 55: 1185–1191.
- 10 Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 1999; 56: 713–718.
- 11 Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991; **41**: 479–486.
- 12 Dooneief G, Marder K, Tang MX, Stern Y. The Clinical Dementia Rating scale: community-based validation of 'profound' and 'terminal' stages. *Neurology* 1996; 46: 1746–1749.
- 13 Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–259.
- 14 Roussos P, Bitsios P, Giakoumaki SG, McClure MM, Hazlett EA, New AS *et al.* CACNA1C as a risk factor for schizotypal personality disorder and schizotypy in healthy individuals. *Psychiatry Res* 2013; **206**: 122–123.
- 15 Roussos P, Giakoumaki SG, Adamaki E, Bitsios P. The influence of schizophreniarelated neuregulin-1 polymorphisms on sensorimotor gating in healthy males. *Biol Psychiatry* 2011; **69**: 479–486.
- 16 Roussos P, Giakoumaki SG, Adamaki E, Georgakopoulos A, Robakis NK, Bitsios P. The association of schizophrenia risk D-amino acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males. *Neuropsychopharmacology* 2011; 36: 1677–1688.
- 17 Roussos P, Giakoumaki SG, Georgakopoulos A, Robakis NK, Bitsios P. The CAC-NA1C and ANK3 risk alleles impact on affective personality traits and startle reactivity but not on cognition or gating in healthy males. *Bipolar Disord* 2011; 13: 250–259.
- 18 Roussos P, Katsel P, Davis KL, Bitsios P, Giakoumaki SG, Jogia J *et al*. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. *Arch Gen Psychiatry* 2012; 69: 7–15.
- 19 Roussos P, Katsel P, Davis KL, Giakoumaki SG, Siever LJ, Bitsios P et al. Convergent findings for abnormalities of the NF-kappaB signaling pathway in schizophrenia. *Neuropsychopharmacology* 2012; **38**: 533–539.
- 20 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; **59 Suppl 20**: 22–33, quiz 34-57.

- 21 Raven J, Raven JC, Court JH. Standard progressive matrices, Raven manual: section 3. In: *Manual for Raven's progressive matrices and vocabulary scales*. Oxford Psychologists Press: Oxford, UK, 2004.
- 22 Birkett P, Sigmundsson T, Sharma T, Toulopoulou T, Griffiths TD, Reveley A et al. Executive function and genetic predisposition to schizophrenia—the Maudsley family study. Am J Med Genet B Neuropsychiatr Genet 2008; 147: 285–293.
- 23 Wechsler D. WAIS-III WMS-III: Technical Manual. Psychological Corporation: San Antonio, TX, USA, 1997.
- 24 Bechara A, Damasio H, Tranel D, Anderson SW. Dissociation Of working memory from decision making within the human prefrontal cortex. J Neurosci 1998; 18: 428–437.
- 25 Fletcher PC, Henson RN. Frontal lobes and human memory: insights from functional neuroimaging. *Brain* 2001; **124**(Pt 5): 849–881.
- 26 Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. *Neuropsychologia* 1990; 28: 1021–1034.
- 27 Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. *Neuropharmacology* 1994; **33**: 575–588.
- 28 Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet* 2006; **2**: e190.
- 29 Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006; **38**: 904–909.
- 30 Roussos P, Katsel P, Davis KL, Siever LJ, Haroutunian V. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch Gen Psychiatry 2012; 69: 1205–1213.
- 31 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; 81: 559–575.
- 32 Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. *Prog Neurobiol* 2004; **74**: 1–58.
- 33 Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. *Neuropsychopharmacology* 1994; 11: 245–256.
- 34 Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. *J Neurophysiol* 1994; **71**: 515–528.
- 35 Muller U, von Cramon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 1998; 18: 2720–2728.
- 36 Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006; 67: e11.
- 37 Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. *Adv Pharmacol* 1998; **42**: 707–711.
- 38 Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature* 1995; **376**: 572–575.
- 39 Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. *Biol Psychiatry* 2009; 66: 997–1004.
- 40 Bitsios P, Roussos P. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. *Pharmacogenomics* 2011; **12**: 559–566.
- 41 Giakoumaki SG, Roussos P, Bitsios P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158-Met polymorphism. *Neuropsychopharmacology* 2008; **33**: 3058–3068.
- 42 Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. *Biol Psychiatry* 2006; 60: 141–151.
- 43 Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF *et al.* Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. *Proc Natl Acad Sci USA* 2003; **100**: 6186–6191.
- 44 Kemppainen N, Ruottinen H, Nagren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. *Neurology* 2000; 55: 205–209.
- 45 Kumar U, Patel SC. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res 2007; 1131: 187–196.
- 46 Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708–3719.
- 47 Kaalund SS, Newburn EN, Ye T, Tao R, Li C, Deep-Soboslay A et al. Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain. *Mol Psychiatry* 2014; **19**: 1258–1266.
- 48 MacDonald SW, Karlsson S, Rieckmann A, Nyberg L, Backman L. Aging-related increases in behavioral variability: relations to losses of dopamine D1 receptors. J Neurosci 2012; 32: 8186–8191.

- 49 Jucaite A, Forssberg H, Karlsson P, Halldin C, Farde L. Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study. *Neuroscience* 2010; 167: 104–110.
- 50 Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. *Nat Rev Genet* 2012; **13**: 227–232.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/

Supplementary Information accompanies the paper on the npj Schizophrenia website (http://www.nature.com/npjschz)